MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Division of Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada.
Mol Cancer Res. 2020 May;18(5):774-786. doi: 10.1158/1541-7786.MCR-18-1370. Epub 2020 Feb 6.
Capicua (CIC) is a transcriptional repressor that counteracts activation of genes in response to receptor tyrosine kinase (RTK)/Ras/ERK signaling. Following activation of RTK, ERK enters the nucleus and serine-phosphorylates CIC, releasing it from its targets to permit gene expression. We recently showed that ERK triggers ubiquitin-mediated degradation of CIC in glioblastoma (GBM). In this study, we examined whether another important downstream effector of RTK/EGFR, the non-RTK c-Src, affects CIC repressor function in GBM. We found that c-Src binds and tyrosine-phosphorylates CIC on residue 1455 to promote nuclear export of CIC. On the other hand, CIC-mutant allele (CIC-Y1455F), that escapes c-Src-mediated tyrosine phosphorylation, remains localized to the nucleus and retains strong repressor function against CIC targets, the oncogenic transcription factors ETV1 and ETV5. Furthermore, we show that the orally available Src family kinase inhibitor, dasatinib, which prevents EGF-mediated tyrosine phosphorylation of CIC and attenuates elevated ETV1 and ETV5 levels, reduces viability of GBM cells and glioma stem cells (GSC), but not of their control cells with undetectable c-Src activity. In fact, GBM cells and GSC expressing the tyrosine-defective CIC mutant (Y1455F) lose sensitivity to dasatinib, further endorsing the effect of dasatinib on Src-mediated tyrosine phosphorylation of CIC. These findings elucidate important mechanisms of CIC regulation and provide the rationale to target c-Src alongside ERK pathway inhibitors as a way to fully restore CIC tumor suppressor function in neoplasms such as GBM. IMPLICATIONS: c-Src tyrosine-phosphorylates CIC exports to cytoplasm and inactivates its repressor function in GBM.
CIC 是一种转录抑制剂,可拮抗受体酪氨酸激酶(RTK)/Ras/ERK 信号转导对基因的激活。在 RTK 激活后,ERK 进入细胞核并使 CIC 丝氨酸磷酸化,使其从靶标上释放出来,从而允许基因表达。我们最近表明,ERK 触发 CIC 在神经胶质瘤(GBM)中的泛素介导的降解。在这项研究中,我们研究了 RTK/EGFR 的另一个重要下游效应物,非 RTK c-Src 是否会影响 GBM 中 CIC 抑制剂的功能。我们发现 c-Src 结合并使 CIC 残基 1455 上的酪氨酸磷酸化,从而促进 CIC 的核输出。另一方面,逃避 c-Src 介导的酪氨酸磷酸化的 CIC 突变等位基因(CIC-Y1455F)仍然定位于细胞核,并对 CIC 靶标,致癌转录因子 ETV1 和 ETV5 保持强烈的抑制功能。此外,我们表明,口服可用的Src 家族激酶抑制剂 dasatinib 可防止 EGF 介导的 CIC 酪氨酸磷酸化,并降低升高的 ETV1 和 ETV5 水平,从而降低 GBM 细胞和神经胶质瘤干细胞(GSC)的活力,但不能降低 c-Src 活性无法检测到的对照细胞的活力。实际上,表达酪氨酸缺陷型 CIC 突变体(Y1455F)的 GBM 细胞和 GSC 对 dasatinib 失去敏感性,进一步证明了 dasatinib 对 CIC 的 Src 介导的酪氨酸磷酸化的作用。这些发现阐明了 CIC 调节的重要机制,并为靶向 c-Src 与 ERK 通路抑制剂一起作为充分恢复 CIC 肿瘤抑制功能的方法提供了依据,如 GBM 等肿瘤。意义:c-Src 酪氨酸磷酸化 CIC 并将其出口到细胞质中,从而使其在 GBM 中的抑制剂功能失活。